Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (76)

II-01Khaled Abduljalil

Simcyp Simulator within the DDMoRe Interoperability Framework – Proof of Concept Cases

Wednesday 15:10-16:30

II-02João Abrantes

Population pharmacokinetic analysis of factor VIII activity following treatment with moroctocog alfa in moderate to severe haemophilia A subjects

Wednesday 15:10-16:30

II-03Malidi Ahamadi

Population exposure –response analysis of “On-Off” time in Individuals with Parkinson Disease following Preladenant Treatment

Wednesday 15:10-16:30

II-04Maurice Ahsman

Modelling and simulation of oral GnRH Antagonist TAK-385 and testosterone-lowering response in Prostate Cancer Patients to Optimize Trial Design and Dose Selection

Wednesday 15:10-16:30

II-05Sihem Bihorel

A plateform PK/PD Model for Antibody Drug Conjugates Induced Myelosuppression

Wednesday 15:10-16:30

II-06

Population pharmacokinetics of the amodiaquine: pooling data across different studies to optimize dosing in neglected populations

Wednesday 15:10-16:30

II-07Hesham Al-Sallami

Redefining normal variability of drug disposition

Wednesday 15:10-16:30

II-08Silvana Alvariza

Autoinduction of phenytoin hepatobiliary secretion as a mechanism for its nonlinear pharmacokinetics

Wednesday 15:10-16:30

II-09Claire Ambery

Balancing efficacy and risk: A case study of Phase 2 dose selection for an anti-inflammatory drug

Wednesday 15:10-16:30

II-10Yasunori Aoki

Model Averaging and Selection methods for model structure and parameter uncertainty quantification

Wednesday 15:10-16:30

II-11Manel Aouri

Population pharmacokinetics analysis of dolutegravir in HIV-1 infected individuals

Wednesday 15:10-16:30

II-12Hyun-moon Back

Development of QT prolongation model in guinea pig with hERG assay-in vivo PK- in-vivo QT effect to guide decision making in early drug discovery

Wednesday 15:10-16:30

II-13Suruchi Bakshi

Explaining the unexpected multi-stationarity in a nonlinear model of prolactin response to dopamine D2 receptor antagonists

Wednesday 15:10-16:30

II-14Violeta Balbas-Martinez

Target evaluation for Inflammatory Bowel Disease (IBD) using a Systems Pharmacology model

Wednesday 15:10-16:30

II-15

Prediction of food effect in the Chinese population using a PBPK model developed in a Caucasian population

Wednesday 15:10-16:30

II-16

Population pharmacokinetics analysis of elvitegravir and cobicistat in HIV-1 infected individuals

Wednesday 15:10-16:30

II-17Charlotte Barker

Simultaneous modelling of antimicrobial pharmacokinetic data from birth to adolescence: using different penicillins to inform a common maturation function

Wednesday 15:10-16:30

II-18Ana Bastos

Using modeling and simulation to design and evaluate dosing strategies for temocillin in haemodialysis patients

Wednesday 15:10-16:30

II-19Levy Batista

Mixed-effects ARX model identification of dynamical systems

Wednesday 15:10-16:30

II-20Brendan Bender

An integrated pharmacokinetic-pharmacodynamic modeling analysis of T-DM1–induced thrombocytopenia and hepatotoxicity in patients with HER2-positive metastatic breast cancer

Wednesday 15:10-16:30

II-21Andrzej Bienczak

Semi-physiological pharmacokinetic/pharmacogenetic model with circadian rhythm for the characterisation of nevirapine pharmacokinetics in African children.

Wednesday 15:10-16:30

II-22Roberto Bizzotto

Mixed-effect deconvolution: a new method applied to oral paracetamol absorption

Wednesday 15:10-16:30

II-23Henrik Bjugård Nyberg

Dismounting Saddles on the Likelihood Surface

Wednesday 15:10-16:30

II-24Dimitra Bon

PK-PD-VK modeling for hepatitis C treatment with the CI and Generalized multiscale model.

Wednesday 15:10-16:30

II-25Charlotte Bon

A target mediated cellular uptake model to assess the asialogycoprotein receptor shuttle capacity in hepatocytes

Wednesday 15:10-16:30

II-26Irina Bondareva

External validation and predictability of nonlinear models for changes in steady–state pharmacokinetics (PK) of carbamazepine (CBZ) and valproate (VPA) due to antiepileptic drug-drug interactions using sparse therapeutic drug monitoring (TDM) data

Wednesday 15:10-16:30

II-27Jennifer Bonner

Building of virtual geriatric cancer populations for physiologically-based pharmacokinetic modelling and simulation in cancer patients greater than 70 years of age

Wednesday 15:10-16:30

II-28Elisa Borella

Development and integration of the WinBUGS connector in the DDMoRe Interoperability Framework

Wednesday 15:10-16:30

II-29Agnieszka Borsuk-De Moor

Population pharmacokinetics of sufentanil after epidural and intravenous administration in children and infants

Wednesday 15:10-16:30

II-30Margreke Brill

Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Wednesday 15:10-16:30

II-31Hannah Britz

Physiologically-Based Pharmacokinetic (PBPK) Modeling of the Dronedarone Drug-Drug Interaction with Digoxin

Wednesday 15:10-16:30

II-32Jantine Brussee

Predictive performance of a CRP and organ failure based pharmacokinetic model for midazolam in critically ill children across external datasets in neonates, children and adults

Wednesday 15:10-16:30

II-33Vincent Buchheit

Added value of the Data Scientist role in a Clinical Pharmacometric group

Wednesday 15:10-16:30

II-34Charles Burdet

Joint modeling of plasma and fecal moxifloxacin pharmacokinetics in healthy volunteers

Wednesday 15:10-16:30

II-35Elisa Calvier

Allometric scaling of clearance in paediatrics: when does the magic of 0.75 fade?

Wednesday 15:10-16:30

II-36Tim Cardilin

Extending the Tumor Static Concentration curve to average doses – a combination therapy example using radiation therapy

Wednesday 15:10-16:30

II-37Luzelena Caro

Population Pharmacokinetics Modeling Characterizes the Higher Grazoprevir Exposure in Japanese Compared to Non-Japanese HCV-Infected Patients

Wednesday 15:10-16:30

II-38Letizia Carrara

Methods and tools for multiscale modelling in Systems Pharmacology: a review

Wednesday 15:10-16:30

II-39Jason Cawley

Competitive brain and body growth model

Wednesday 15:10-16:30

II-40Pascal Chanu

A model to predict progression free survival in patients with previously untreated HER2-positive progressive or recurrent locally advanced or metastatic breast cancer based on tumor growth inhibition metrics

Wednesday 15:10-16:30

II-41Aziz Chaouch

Building up a posteriori percentiles for Therapeutic Drug Concentration Monitoring

Wednesday 15:10-16:30

II-42

Pharmacometrics workflow: standards for provenance capture and workflow definition

Wednesday 15:10-16:30

II-43Christophe Chassagnole

Modelling the Emergence of Resistance to Chemotherapeutics with Virtual Tumour

Wednesday 15:10-16:30

II-44Chunli Chen

Assessment of Pharmacodynamic Interactions in the Mycobacteria Tuberculosis Infected Mouse using The Multistate Tuberculosis Pharmacometric Model and the General Pharmacodynamic Interaction Model

Wednesday 15:10-16:30

II-45

Comparison of Recursive Partitioning Analysis and Receiver Operating Characteristic (ROC) Analysis for Patient Identification

Wednesday 15:10-16:30

II-46Maxwell Chirehwa

Semi-mechanistic pharmacokinetic model for Isoniazid and Acetyl isoniazid in a cohort of TB/HIV co-infected patients

Wednesday 15:10-16:30

II-47Hyewon Chung

Population pharmacokinetics of F-ara-A after fludarabine administration in pediatric hematopoietic stem cell transplantation patients

Wednesday 15:10-16:30

II-48

A model to predict progression-free survival in patients with renal cell carcinoma based on week 8 change in tumor size

Wednesday 15:10-16:30

II-49Yumi Cleary

Physiologically –based pharmacokinetic (PBPK) and population PK (PPK) modeling for basimglurant – assessment of predicted variability by the PBPK model and its utility

Wednesday 15:10-16:30

II-50Oskar Clewe

Pre-clinical Susceptibility Characterization and Pharmacodynamic Interaction Assessment Using the Multistate Tuberculosis Pharmacometric Model

Wednesday 15:10-16:30

II-51Pieter Colin

Propofol breath monitoring as a potential tool to improve the prediction of intraoperative plasma concentrations

Wednesday 15:10-16:30

II-52Emmanuelle Comets

Operational characteristics of saemix, an R package implementing the SAEM algorithm

Wednesday 15:10-16:30

II-53Valerie Cosson

Wednesday 15:10-16:30

II-54Sinziana Cristea

Maturation of Glomerular Filtration throughout the paediatric age-range; a comparison of different functions

Wednesday 15:10-16:30

II-55Damien Cronier

PK/PD Modeling of Overall and Progression-Free Survival in Advanced Soft Tissue Sarcoma Patients Treated With Olaratumab in Combination with Doxorubicin.

Wednesday 15:10-16:30

II-56Salvatore D'Agate

Optimisation of weight-banded dosing regimens of amoxicillin in neonates and young infants with sepsis

Wednesday 15:10-16:30

II-57André Dallmann

Validation of a Population Physiologically-Based Pharmacokinetic Model for Pregnant Women

Wednesday 15:10-16:30

II-58Fabrizia D'Antonio

Effect of psychotic subtypes on cognitive trajectories in Alzheimer’s disease Neuroimaging Initiative ADNI2.

Wednesday 15:10-16:30

II-59Pieter De Cock

piperacillin-tazobactam pharmacokinetics in critically ill children: implications on adequate dosing regimens

Wednesday 15:10-16:30

II-60Miné De Kock

Pharmacokinetics of Sulfadoxine and Pyrimethamine for intermittent preventive treatment of malaria during Pregnancy and after delivery.

Wednesday 15:10-16:30

II-61Bernardo de Miguel Lillo

Modeling the dynamics of alanine aminotransferase in advanced cancer patients treated with kahalalide F

Wednesday 15:10-16:30

II-62Mailys De Sousa Mendes

A physiologically based pharmacokinetic model for a drug metabolized by several CYP450 during pregnancy

Wednesday 15:10-16:30

II-63Aurelia de Vries Schultink

Pharmacokinetics of MCLA-128 in cynomolgus monkeys and extrapolation to humans to support selection of first-in-human dose

Wednesday 15:10-16:30

II-64Brenda de Winter

Pharmacokinetics of Pentobarbital in Pediatric Status Epilepticus Patients

Wednesday 15:10-16:30

II-65Wilbert de Witte

High drug-target association rates increase the duration of in vivo target occupancy

Wednesday 15:10-16:30

II-66Amelia Deitchman

Tetracycline against Pseudomonas aeruginosa: Pharmacokinetic/Pharmacodynamic Modeling of In Vitro Time-Kill Curves

Wednesday 15:10-16:30

II-67Laurence Del Frari

Predicting human pharmacokinetics of monoclonal antibodies by allometric translation from preclinical data: a case study

Wednesday 15:10-16:30

II-68Ivan Demin

Guidance on dose-finding studies for biostatisticians and pharmacometricians: a Pharmacometrics perspective

Wednesday 15:10-16:30

II-69Paolo Denti

Population Pharmacokinetics of Levofloxacin in South African children.

Wednesday 15:10-16:30

II-70Christiane Dings

Pharmacokinetic and Pharmacodynamic Modeling of Acetylsalicylic Acid and its Major Metabolite Salicylic Acid

Wednesday 15:10-16:30

II-72Thomas Dorlo

Translational PKPD modeling framework to assess the predictive performance of a preclinical visceral leishmaniasis hamster model

Wednesday 15:10-16:30

II-73Anne-Gaelle Dosne

Robust QT prolongation assessment using model-averaging

Wednesday 15:10-16:30

II-74Erwin Dreesen

Anti-drug antibodies, low serum albumin and high C-reactive protein increase infliximab clearance in patients with inflammatory bowel disease: a population pharmacokinetic study of the TAXIT trial

Wednesday 15:10-16:30

II-75Stefanie Drescher

An Integrated Model for Glucose and Insulin Regulation in Bariatric Surgery Patients following Intravenous Glucose Tolerance Test

Wednesday 15:10-16:30

II-76Hélder Duarte

Amikacin in premature newborn: a new therapeutic proposal from a PopPK model

Wednesday 15:10-16:30

II-77

Joint modelling of pain intensity and informative dropout in moderate to severe chronic pain patients

Wednesday 15:10-16:30